A study to compare the reduction of blood sugar,blood pressure,cholesterol and inflammatory benefits momordica charantia tablet with regular therapy in metabolic syndrome patients

An open label, prospective clinical comparative study to assess the anti-inflammatory benefit of momordica charantia tablet in metabolic syndrome. - not applicable

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025569

Enrollment

Registered

2020-06-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E138- Other specified diabetes mellituswith unspecified complications

Interventions

Intervention1: Momordica Charantia Tablet 1G TDS FOR 3 MONTHS: TO Study The Anti-Hypertensive Anti-Diabetic And Anti-Lipedemic,Anti-Inflammatory Benefit Of Momordica Tablet As Add On Therapy With The

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients already on OLmesartan 20mg OD and Metformin 500mgOD and Atorvastatin 10 mg OD 2.Prediagnosed Metabolic syndrome patients with Diet and life style modifications 3.Age >25 years 4.Both Male and Female 5.Triglycerides >150 mg/dl 6.FBS >100 mg/dl 7.PPBS >140 mg/dl 8.BP >130/85 mmHg 9.HbA1C -5.7-6.4

Exclusion criteria

Exclusion criteria: 1.Patients with Coronary artery disease /storke 2.Patients with Aspirin/NSAIDS/Steroid/Febuxostat/Statin/Thaizide 3.Patients with Injuries/Arthritis/Hypothyroidism/Nephrotic syndrome 4.Patients on native treatment/ayurveda/siddha treatment/on any alternative treatment 5.Pregnancy/Lactation/Heavy Alcohol Consumption 6.Blood pressure >150/100mmHg 7.HbA1C >7.4 8.Triglycerides >400 mg/dl 9.Patients on more than one drug for hypertension other than Olmesartan 20mg OD and drugs other than Metformin 500MG OD for Diabetes and drugs for elevated cholesterol other than Atorvastatin 10 mg OD

Design outcomes

Primary

Measure	Time frame
To compare the clinical effectiveness of Momordica Charantia Tablet with Standard drug therapy in the newly diagnosed Metabolic Syndrome patientsTimepoint: Pre Medication Parmeters -BP,Body Weight,Waist Circumference,BMI,FBS,PPBS,HbA1C,SOD,MDA,HS-CRP will be done 1 day prior to intiating Medications	—

Secondary

Measure	Time frame
TO IDENTIFY THE ANTI-INFLAMMATORY BENEFIT OF MOMORDICA CHARANTIA TABLET IN PATIENTS WITH METABOLIC SYNDROME USING MARKERS OF OXIDATIVE STRESS SOD,MDA,HS-CRPTimepoint: POST MEDICATION PARAMETERS-BP,BMI,BODYWEIGHT,WAIST CIRCUMFERENCE,FBS PPBS,HbA1C,HS CRP,SOD,MDA AFTER 3 MONTHS OF MEDICATION 1 DAY LATER PARAMETERS WILL BE DONE	—

Countries

India

Contacts

Public ContactDr K BHUVANESWARI

PSG Institute of Medical science and Research

nandabhuvana@gmail.com9894769934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026